Conservation of the enzyme-like activity and biocompatibility of CeO2 nanozymes in simulated body fluids

dc.contributor.authorFernández Varo, Guillermo
dc.contributor.authorZeng, Muling
dc.contributor.authorZhang, Xu
dc.contributor.authorTang, Jie
dc.contributor.authorLiu, Xingfei
dc.contributor.authorLin, Yichao
dc.contributor.authorGuo, Dongdong
dc.contributor.authorZhang, Yuping
dc.contributor.authorJu, Shijie
dc.contributor.authorWang, Ya-Chao
dc.contributor.authorZhou, Xiangyu
dc.contributor.authorCasals, Gregori
dc.contributor.authorCasals, Eudald
dc.date.accessioned2025-03-19T15:41:28Z
dc.date.available2025-03-19T15:41:28Z
dc.date.issued2023-08-10
dc.date.updated2025-03-19T15:41:28Z
dc.description.abstractCerium oxide nanozymes (CeO2NZs) are attracting vast attention due to their antioxidant and catalytic properties and mimic the activities of multiple endogenous enzymes. However, as is the case for nanomedicines in general, the success in showing their unique medical applications has not been matched by an understanding of their pharmacokinetics, which is delaying their implementation in clinical settings. Furthermore, the data of their modifications in body fluids and the impact on their activity are scarce. Herein, two types of widely used CeO2NZs, electrostatically stabilized and coated with a mesoporous silica shell, were exposed to simulated saliva and lung, gastric and intestinal fluids, and cell culture media. Their physicochemical modifications and bioactivity were tracked over time up to 15 days combining the data of different characterization techniques and biological assays. The results show that the biocompatibility and antioxidant activity are retained in all cases despite the different evolution behaviors in different fluids, including agglomeration. This work provides an experimental basis from a pharmacokinetic perspective that supports the therapeutic effectiveness of CeO2NZs observed in vivo for the treatment of many conditions related to chronic inflammation and cancer, and suggests that they can be safely administered through different portals of entry including intravenous injection, oral ingestion or inhalation.
dc.format.extent34 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec757647
dc.identifier.idimarina9377650
dc.identifier.issn2040-3364
dc.identifier.pmid37609757
dc.identifier.urihttps://hdl.handle.net/2445/219851
dc.language.isoeng
dc.publisherRoyal Society of Chemistry
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1039/d3nr03524g
dc.relation.ispartofNanoscale, 2023, vol. 15, num.35, p. 14365-14379
dc.relation.urihttps://doi.org/10.1039/d3nr03524g
dc.rights(c) Zeng, M. et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Infermeria Fonamental i Clínica)
dc.subject.classificationBiocompatibilitat
dc.subject.classificationHumors corporals
dc.subject.classificationAntioxidants
dc.subject.otherBiocompatibility
dc.subject.otherBody fluids
dc.subject.otherAntioxidants
dc.titleConservation of the enzyme-like activity and biocompatibility of CeO2 nanozymes in simulated body fluids
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
891045.pdf
Mida:
3.86 MB
Format:
Adobe Portable Document Format